Indications for: TRADJENTA

Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy.

Limitations of Use:

Not for treatment of type 1 diabetes. Not studied in patients with a history of pancreatitis.

Adult Dosage:

5mg once daily.

Children Dosage:

<18yrs: not established.

TRADJENTA Warnings/Precautions:

Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms; evaluate and consider discontinuing if develops. Monitor for signs/symptoms of pancreatitis, serious hypersensitivity reactions, severe joint pain, or bullous pemphigoid; discontinue if suspected or occurs. History of angioedema to other DPP-4 inhibitors. Pregnancy. Nursing mothers.

TRADJENTA Classification:

Dipeptidyl peptidase-4 (DPP-4) inhibitor.

TRADJENTA Interactions:

Antagonized by strong P-gp or CYP3A4 inducers (eg, rifampin); consider alternatives to linagliptin if used in combination. May need lower doses of the concomitant insulin secretagogue (eg, sulfonylurea) or insulin to reduce risk of hypoglycemia.

Adverse Reactions:

Nasopharyngitis, diarrhea, cough, hypoglycemia; hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, exfoliative skin conditions, bronchial hyperreactivity), myalgia, pancreatitis, severe and disabling arthralgia, bullous pemphigoid.

Generic Drug Availability:


How Supplied:

Tabs—30, 90